Triple approach strategy for patients with locally advanced pancreatic carcinoma

HPB

Volumn 15, Issue 8, 2013, Pages 623-627

  Giardino, Alessandro ^a   Girelli, Roberto ^a   Frigerio, Isabella ^a   Regi, Paolo ^a   Cantore, Maurizio ^b   Alessandra, Auriemma ^b   Lusenti, Annita ^b   Salvia, Roberto ^c   Bassi, Claudio ^c   Pederzoli, Paolo ^a  

^a Department of Radiology   (Italy)

^b Oncology Department   (Italy)

^c UNIVERSITY OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CISPLATIN; EPIRUBICIN; GEMCITABINE; OXALIPLATIN;

ACUTE PANCREATITIS; ADULT; ADVANCED CANCER; AGED; BILE DUCT FISTULA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CHEMORADIOTHERAPY; CONFERENCE PAPER; DRUG DOSE REDUCTION; DUODENUM INJURY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; HEMOPERITONEUM; HUMAN; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PANCREAS CARCINOMA; PANCREAS FISTULA; PORTAL VEIN THROMBOSIS; PSYCHOSIS; RADIOFREQUENCY ABLATION; RETROSPECTIVE STUDY; SURVIVAL RATE; THROMBOCYTOPENIA;

EID: 84880176032     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1111/hpb.12027     Document Type: Conference Paper

References (27)

1. Tabernero J, Maraculla T,. (2009) Changing the paradigm in conducting randomized clinical studies in advanced pancreatic cancer: an opportunity for better clinical development. J Clin Oncol 27: 5487-5498.
2. Bayraktar S, Bayraktar UD, Rocha-Lima CM,. (2010) Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer. World J Gastroenterol 16: 673-682.
3. Kindler HL, Niedzwiecki D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, et al. (2010) Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 28: 3617-3622.
4. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: 1960-1966.
5. Van Cutsem E, Vervenne WL, Bennouna J, Humblet Y, Gill S, Van Laethem JL, et al. (2009) Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 27: 2231-2237.
6. Philip PA, Benedetti J, Crless CL, Wong R, O'Reilly EM, Flynn PJ, et al. (2010) Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: southwest oncology group-directed intergroup trial S0205. J Clin Oncol 28: 3605-3610.
7. Raut CP, Tsen JF, Sun CC, Wang H, Wolff RA, Crane CH, et al. (2007) Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg 246: 52-60.
8. Girelli R, Frigerio I, Salvia R, Barbi E, Tinazzi Martini P, Bassi C,. (2010) Feasibility and safety of radiofrequency ablation for locally advanced pancreatic cancer. Br J Surg 97: 220-225.
9. D'Onofrio M, Barbi E, Girelli R, Martone E, Gallotti A, Salvia R, et al. (2010) Radiofrequancy ablation of locally advanced pancreatic adenocarcinoma: an overview. World J Gastroenterol 16: 3478-3483.
10. Huguet F, André T, Hammel P, Artru P, Balosso J, Selle F, et al. (2007) Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 25: 326-331.
11. Blackstock AW, Tepper JE, Niedwiecki D, Hollis DR, Mayer RJ, Tempero MA,. (2003) Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas. Int J Gastrointest Cancer 34: 107-116.
12. Brade A, Brierley J, Oza A, Gallinger S, Cummings B, Maclean M, et al. (2007) Concurrent gemcitabine and radiotherapy with and without neoadjuvant gemcitabine for locally advanced unresectable or resected pancreatic cancer: a phase I-II study. Int J Radiat Oncol Biol Phys 67: 1027-1036.
13. Link KH, Gansauge F, Gorich J, Leder GH, Rilinger N, Beger HG,. (1997) Palliative and adjuvant regional chemotherapy in pancreatic cancer. Eur J Surg Oncol 23: 409-414.
14. Cantore M, Serio G, Pederzoli P, Mambrini A, Iacono C, Pulica C, et al. (2006) Adjuvant intra-arterial 5-fluorouracil, leucovorin, epirubicin and carboplatin with or without systemic gemcitabine after curative resection for pancreatic adenocarcinoma. Cancer Chemother Pharmacol 58: 504-508.
15. Kaplan EL, Meier P,. (1958) Non parametric estimation from incomplete observation. J Am Stat Assoc 53: 457-481.
16. Cox DR,. (1972) Regression models and life tables (with discussion). J R Stat Soc Series B Stat Methodol 34: 187-220.
17. Taylor JMC, Braun TM, Li Z,. (2006) Comparing an experimental agent to standard agent; relative merits of a one-arm or randomized two-arms phase II design. Clin Trials 3: 335-348.
18. Köninger J, Wente MN, Müller MW, Gutt CN, Friess H, Büchler MW,. (2007) Surgical palliation in patients with pancreatic cancer. Langenbecks Arch Surg 392: 13-21.
19. André T, Balosso J, Louvet C, Hannoun L, Houry S, Huguier M, et al. (2000) Combined radiotherapy and chemotherapy (cisplatin and 5-fluorouracil) as palliative treatment for localized unresectable or adjuvant treatment for resected pancreatic adenocarcinoma. Results of a feasibility study. Int J Radiat Oncol Biol Phys 46: 903-911.
20. McGahan JP, Brock JM, Tesluk H, Gu WZ, Schneider P, Browning PD,. (1992) Hepatic ablation with use of radiofrequency electrocautery in the animal model. J Vasc Interv Radiol 3: 291-297.
21. Bartholomae WC, Rininsland FH, Eisemberg JC, Boehm BO, Lehmann PV, Tary-Lehmann M,. (2004) T cell immunity induced by live, necrotic and apoptotic tumor cells. J Immunol 73: 1012-1022.
22. Collins JM,. (1984) Pharmacologic rationale for regional drug delivery. J Clin Oncol 2: 498-504.
23. Cantore M, Fiorentini G, Luppi G, Rosati G, Caudana R, Piazza E, et al. (2004) Gemcitabine versus FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: a prospective, randomized phase III trial of the Italian Society for Integrated Locoregional Therapy in Oncology. J Chemother 16: 589-594.
24. Mambrini A, Pacetti P, Del Freo A, Della Seta R, Pezzuolo D, Torri T, et al. (2009) Gemcitabine-capecitabine plus intra-arterial epirubicin-cisplatin in pretreated pancreatic cancer patients: a phase I study. Anticancer Res 29: 1547-1550.
25. Boeck S, Hinke A, Wilkowsky R, Heinemann V,. (2007) Importance of performance status for treatment outcome in advanced pancreatic cancer. World J Gastroenterol 13: 224-227.
26. Bernhard J, Dietrich D, Glimelius B, Hess V, Bodoky G, Scheithauer W, et al. (2010) Estimating prognosis and palliation based on tumour marker CA 19-9 and quality of life indicators in patients with advanced pancreatic cancer receiving chemotherapy. Br J Cancer 103: 1318-1324.
27. Philip A, Mooney M, Jaffe D, Eckhardt G, Moore M, Meropol N, et al. (2009) Consensus report of the National Cancer Institute Clinical Trials Planning Meeting on pancreas cancer treatment. J Clin Oncol 27: 5660-5669.